Cargando…
RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
Oestrogen receptor ɑ (ERɑ) is overexpressed in two‐thirds of all breast cancers and involves in development and breast cancer progression. Although ERɑ‐positive breast cancer could be effective treated by endocrine therapy, the endocrine resistance is still an urgent clinical problem. Thus, further...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111850/ https://www.ncbi.nlm.nih.gov/pubmed/29974997 http://dx.doi.org/10.1111/jcmm.13694 |
_version_ | 1783350746030276608 |
---|---|
author | Liu, Zhenhua Zhang, Jinghang Xu, Juntao Yang, Huijie Li, Xin Hou, Yingxiang Zhao, Yan Xue, Min Wang, Beibei Yu, Na Yu, Sifan Niu, Gang Wu, Gaosong Li, Xiumin Wang, Hui Zhu, Jian Zhuang, Ting |
author_facet | Liu, Zhenhua Zhang, Jinghang Xu, Juntao Yang, Huijie Li, Xin Hou, Yingxiang Zhao, Yan Xue, Min Wang, Beibei Yu, Na Yu, Sifan Niu, Gang Wu, Gaosong Li, Xiumin Wang, Hui Zhu, Jian Zhuang, Ting |
author_sort | Liu, Zhenhua |
collection | PubMed |
description | Oestrogen receptor ɑ (ERɑ) is overexpressed in two‐thirds of all breast cancers and involves in development and breast cancer progression. Although ERɑ‐positive breast cancer could be effective treated by endocrine therapy, the endocrine resistance is still an urgent clinical problem. Thus, further understanding of the underlying mechanisms ERɑ signalling is critical in dealing with endocrine resistance in breast cancer patients. MCF‐7 and T47D breast cancer cell lines are used to carry out the molecular biological experiments. Western blot is used to assess the relative protein level of ERɑ, RNF168 and actin. Real‐time PCR is used the measure the relative ERɑ‐related gene mRNA level. Luciferase assay is used to measure the relative ERɑ signalling activity. Chromatin immunoprecipitation is used to measure the RNF168 binding affinity to ERɑ promoter regions. WST assay and flow cytometry are used to measure the cell proliferation capacity. We use Student's t test and one‐way ANOVA test for statistical data analysis. Here, we report an important role in ERɑ‐positive breast cancer cells for RNF168 protein in supporting cell proliferation by driving the transcription of ERɑ. RNF168 is highly expressed in breast cancer samples, compared with normal breast tissue. In patients with breast cancer, RNF168 expression level is correlated with poor endocrine treatment outcome. Depletion of RNF168 causes decreased cell proliferation in MCF‐7 and T47D cells. Besides, depletion RNF168 reduced mRNA level of ERɑ and its target genes, such as PS2 and GREB1. Chromatin immunoprecipitation revealed that ERɑ transcription is associated with RNF168 recruitment to ERɑ promoter region, suggesting that transcriptional regulation is one mechanism by which RNF168 regulates ERɑ mRNA level and ERɑ signalling in breast cancer cells. RNF168 is required for ERɑ‐positive breast cancer cell proliferation and facilitate ERɑ signalling activity possibly through promoting transcription of ERɑ. |
format | Online Article Text |
id | pubmed-6111850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61118502018-09-01 RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation Liu, Zhenhua Zhang, Jinghang Xu, Juntao Yang, Huijie Li, Xin Hou, Yingxiang Zhao, Yan Xue, Min Wang, Beibei Yu, Na Yu, Sifan Niu, Gang Wu, Gaosong Li, Xiumin Wang, Hui Zhu, Jian Zhuang, Ting J Cell Mol Med Original Articles Oestrogen receptor ɑ (ERɑ) is overexpressed in two‐thirds of all breast cancers and involves in development and breast cancer progression. Although ERɑ‐positive breast cancer could be effective treated by endocrine therapy, the endocrine resistance is still an urgent clinical problem. Thus, further understanding of the underlying mechanisms ERɑ signalling is critical in dealing with endocrine resistance in breast cancer patients. MCF‐7 and T47D breast cancer cell lines are used to carry out the molecular biological experiments. Western blot is used to assess the relative protein level of ERɑ, RNF168 and actin. Real‐time PCR is used the measure the relative ERɑ‐related gene mRNA level. Luciferase assay is used to measure the relative ERɑ signalling activity. Chromatin immunoprecipitation is used to measure the RNF168 binding affinity to ERɑ promoter regions. WST assay and flow cytometry are used to measure the cell proliferation capacity. We use Student's t test and one‐way ANOVA test for statistical data analysis. Here, we report an important role in ERɑ‐positive breast cancer cells for RNF168 protein in supporting cell proliferation by driving the transcription of ERɑ. RNF168 is highly expressed in breast cancer samples, compared with normal breast tissue. In patients with breast cancer, RNF168 expression level is correlated with poor endocrine treatment outcome. Depletion of RNF168 causes decreased cell proliferation in MCF‐7 and T47D cells. Besides, depletion RNF168 reduced mRNA level of ERɑ and its target genes, such as PS2 and GREB1. Chromatin immunoprecipitation revealed that ERɑ transcription is associated with RNF168 recruitment to ERɑ promoter region, suggesting that transcriptional regulation is one mechanism by which RNF168 regulates ERɑ mRNA level and ERɑ signalling in breast cancer cells. RNF168 is required for ERɑ‐positive breast cancer cell proliferation and facilitate ERɑ signalling activity possibly through promoting transcription of ERɑ. John Wiley and Sons Inc. 2018-07-05 2018-09 /pmc/articles/PMC6111850/ /pubmed/29974997 http://dx.doi.org/10.1111/jcmm.13694 Text en © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Liu, Zhenhua Zhang, Jinghang Xu, Juntao Yang, Huijie Li, Xin Hou, Yingxiang Zhao, Yan Xue, Min Wang, Beibei Yu, Na Yu, Sifan Niu, Gang Wu, Gaosong Li, Xiumin Wang, Hui Zhu, Jian Zhuang, Ting RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation |
title |
RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation |
title_full |
RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation |
title_fullStr |
RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation |
title_full_unstemmed |
RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation |
title_short |
RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation |
title_sort | rnf168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111850/ https://www.ncbi.nlm.nih.gov/pubmed/29974997 http://dx.doi.org/10.1111/jcmm.13694 |
work_keys_str_mv | AT liuzhenhua rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT zhangjinghang rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT xujuntao rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT yanghuijie rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT lixin rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT houyingxiang rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT zhaoyan rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT xuemin rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT wangbeibei rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT yuna rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT yusifan rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT niugang rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT wugaosong rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT lixiumin rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT wanghui rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT zhujian rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation AT zhuangting rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation |